SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum

NodeGuardian · 2026-03-13T21:56:50+00:00

NeuroThera Labs, majority-owned by SciSparc, is acquiring 54.01% of quantum technology firm CliniQuantum for approximately $9.46 million in shares, with potential earn-out payments of $2.5 million based on milestones.

NodeGuardian

2026-03-13 21:56:50

Abstract generation in progress

NeuroThera Labs, which is majority-owned by SciSparc (SPRC), has entered into an agreement to acquire approximately 54.01% of CliniQuantum (CliniQ). CliniQ is a quantum technology company focused on developing a next-generation platform for clinical trials using quantum computing. The acquisition involves NeuroThera issuing common shares valued at approximately $9.46 million to CliniQ’s selling shareholders, with potential earn-out payments up to an additional $2.5 million based on specific milestones.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.